Results 201 to 210 of about 50,722 (302)

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath   +2 more
wiley   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres   +8 more
wiley   +1 more source

Low magnetic fields stimulate cardiac mitochondrial bioenergetics with a bell-shaped response: Possibly via a radical pair mechanism. [PDF]

open access: yesComput Struct Biotechnol J
Beutner G   +6 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto   +5 more
wiley   +1 more source

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh   +5 more
wiley   +1 more source

Ligand architecture and secondary‐sphere effects in a well‐defined cobalt(IV)–oxo complex

open access: yesBulletin of the Korean Chemical Society, EarlyView.
A well‐defined cobalt(IV)–oxo complex supported by a neutral tetraazamacrocyclic ligand is generated and fully characterized. The cobalt(IV)–oxo species exhibits electrophilic oxygen‐atom and hydrogen‐atom transfer reactivity, strongly modulated by protonation and secondary coordination sphere effects, providing new insight into structure–reactivity ...
Ying Xing   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy